CN104173342A - (R)-lansoprazole composition - Google Patents
(R)-lansoprazole composition Download PDFInfo
- Publication number
- CN104173342A CN104173342A CN201410367285.2A CN201410367285A CN104173342A CN 104173342 A CN104173342 A CN 104173342A CN 201410367285 A CN201410367285 A CN 201410367285A CN 104173342 A CN104173342 A CN 104173342A
- Authority
- CN
- China
- Prior art keywords
- dexlansoprazole
- coating
- preparation
- solution
- lansoprazole
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention relates to a (R)-lansoprazole composition which comprises the following components in parts by weight: 0.5 to 2 parts of (R)-lansoprazole, 0.6 part of antacid, 0.5 part of an antioxidant and 0.3 part of a disintegrating agent. The antacid, the antioxidant and the like are added into the traditional (R)-lansoprazole, so that the stability of the (R)-lansoprazole is obviously improved. Thus, the lasting activity of the (R)-lansoprazole is maintained, and reaction by-products generated during the storing of the (R)-lansoprazole are reduced. As a result, the stability of a (R)-lansoprazole preparation can be improved.
Description
Technical field
The present invention relates to medical technical field, relate in particular to a kind of Dexlansoprazole compositions.
Background technology
Lansoprazole be developed by Japanese Takeda Pharmaceutical Company Limited there is the inhibiting benzimidazoles derivative of gastric acid secretion; first synthetic by Nohara Akira etc. in 1986; and by this compound of clinical trial certificate there is antiulcer activity, control gastric acid secretion, the feature such as protection gastric mucosa, toxicity is low, went on the market in Japan first in 1992.Get permission listing in the U.S. in June, 2004.Lansoprazole is because importing fluorine at 4 side chains of pyridine ring, and there is a trifluoro ethoxy substituent group, its bioavailability is improved more than 30% compared with omeprazole, lipotropy is also better than omeprazole, therefore these product can be promptly under acid condition see through parietal cell film and change sulfenic acids and sulfenic acids derivant into and bring into play drug effect, the bacteriostatic activity of HP are increased to 4 times of omeprazole.
Dexlansoprazole is the enantiomer of proton pump inhibitor lansoprazole.The drug effect that proposes Dexlansoprazole and S-lansoprazole in WO9938512, WO9938513 is all apparently higher than the lansoprazole of racemization, and toxic and side effects is but lower than the lansoprazole of racemization.Existing result of study shows, the drug effect of Dexlansoprazole is better than the lansoprazole of laevo-configuration, and the drug effect of raceme is mainly from Dexlansoprazole.
Research shows, Dexlansoprazole poor stability, easily degraded under acid, oxidation, hot conditions.At present, in numerous patents of invention about lansoprazole preparation, be mainly to add alkaline stabiliser such as, to increase the stability of medicine, patent CN103006654B, CN101953812B etc.But in long-term put procedure, find, in preparation finished product, related substance is along with the time increases and increases.
Summary of the invention
The object of the invention is to solve the poor technical problem of Dexlansoprazole composition stable in prior art, slow down the generation of its catabolite in long-term put procedure, be beneficial to storage and the effectiveness of preparation finished product.
A kind of Dexlansoprazole compositions of the present invention, described compositions is mixed and is formed by the component of following weight portion:
Dexlansoprazole 0.5-2 part;
0.6 part of antacid;
0.5 part of antioxidant;
0.3 part of disintegrating agent.
Described antacid is magnesium carbonate.
Described antioxidant is sodium sulfite.
Described disintegrating agent is low substituted hydroxy-propyl.
The preparation of described compositions is more than one preparations in enteric coatel tablets, enteric coated capsule, slow releasing capsule, enteric coated micropill.
Described Dexlansoprazole is 0.5 part.
Described Dexlansoprazole is 1.0 parts.
Described Dexlansoprazole is 1.5 parts.
In the present invention, antacid magnesium carbonate can improve the stability of Dexlansoprazole in solution.
In the present invention, antioxidant sodium sulfite can improve the stability of capsule in long-term put procedure.
In the present invention, disintegrating agent low substituted hydroxy-propyl can be accelerated the dissolution rate of Dexlansoprazole from capsule, improves the functioning efficiency of Dexlansoprazole.
In the present invention, Dexlansoprazole is pharmaceutical grade, purchases in market.
In the present invention, Dexlansoprazole composite preparation can also be conventional tablet, dispersible tablet, chewable tablet, slow releasing tablet, capsule, granule, injection preparation.
A kind of Dexlansoprazole compositions of the present invention, by add antacid, antioxidant etc. in traditional Dexlansoprazole, can obviously improve the stability of Dexlansoprazole, make the activity keeping of Dexlansoprazole more lasting, reduce Dexlansoprazole in put procedure, the generation of byproduct of reaction, is conducive to improve the stability of Dexlansoprazole preparation.
Detailed description of the invention
A kind of Dexlansoprazole compositions of the present invention, described compositions is mixed and is formed by the component of following weight portion:
Dexlansoprazole 0.5-2 part;
0.6 part of antacid;
0.5 part of antioxidant;
0.3 part of disintegrating agent.
Described antacid is magnesium carbonate.
Described antioxidant is sodium sulfite.
Described disintegrating agent is low substituted hydroxy-propyl.
The preparation of described compositions is more than one preparations in conventional tablet, dispersible tablet, chewable tablet, slow releasing tablet, capsule, granule, injection preparation.
Described Dexlansoprazole is 0.5 part.
Described Dexlansoprazole is 1.0 parts.
Described Dexlansoprazole is 1.5 parts.
embodiment 1
Prescription: Dexlansoprazole enteric coatel tablets
| Pastille label: | ? |
| Dexlansoprazole | 15mg |
| Magnesium carbonate | 36mg |
| Sodium sulfite | 30mg |
| Low-substituted hydroxypropyl cellulose | 18mg |
| Lactose | 21mg |
| Microcrystalline Cellulose | 20mg |
| Hydroxypropyl methylcellulose | 15 mg |
| Isolation coat layer (pressing label weightening finish 10% ~ 12% calculates): | ? |
| Hydroxypropyl methylcellulose | 7.5 mg |
| Titanium dioxide | 3mg |
| Pulvis Talci | 4.5mg |
| Enteric coat layer (by 15% calculating of increasing weight after bag sealing coat): | ? |
| L30D-55 | 70mg |
| Pulvis Talci | 5mg |
| PEG6000 | 2mg |
| Titanium dioxide | 2mg |
Preparation technology:
(1) preparation of pastille label
Dexlansoprazole is crossed 80 mesh sieves with lactose, microcrystalline Cellulose, magnesium carbonate, sodium sulfite, low-substituted hydroxypropyl cellulose and is mixed homogeneously, compound concentration 5% hydroxypropyl methylcellulose solution is as binding agent, add in the medicated powder of mix homogeneously and mix homogeneously, cross 18 mesh sieves and granulate.Put into 40 DEG C, baking oven and be dried 12 hours, cross 20 mesh sieve granulate, tabletting, obtains label.
(2) preparation of isolation coat layer
Take recipe quantity titanium dioxide, Pulvis Talci is scattered in concentration 5% hydroxypropyl methylcellulose solution, after stirring, grinds 10min in colloid mill; Obtain sealing coat coating solution.Pastille label is placed in to coating pan, coating.Coating is placed on drying under reduced pressure 12h in 40 DEG C of vacuum drying ovens.
(3) preparation of enteric coat layer
Take recipe quantity L30D-55 and add appropriate purified water dilution, obtain solution A; Take recipe quantity PEG6000 and be dissolved in purified water, add recipe quantity Pulvis Talci, titanium dioxide, after stirring, in colloid mill, grind 10min, obtain solution B; Solution B, under stirring condition, is added in solution A, after low rate mixing 30min, cross 80 mesh sieves; Obtain enteric coating liquid.Label is placed in to coating pan, coating.Coating is placed on drying under reduced pressure 12h in 40 DEG C of vacuum drying ovens.
embodiment 2
Prescription: Dexlansoprazole enteric coated capsule
| Contain pill core: | ? |
| Dexlansoprazole | 30mg |
| Magnesium carbonate | 36mg |
| Sodium sulfite | 30mg |
| Low-substituted hydroxypropyl cellulose | 18mg |
| Celphere | 40mg |
| Hydroxypropyl cellulose | 15 mg |
| Isolation coat layer (pressing ball core weightening finish 10% ~ 12% calculates): | ? |
| Hydroxypropyl methylcellulose | 7.5 mg |
| Titanium dioxide | 3mg |
| Pulvis Talci | 4.5mg |
| Enteric coat layer (by 15% calculating of increasing weight after bag sealing coat): | ? |
| L30D-55 | 70mg |
| Pulvis Talci | 5mg |
| PEG6000 | 2mg |
| Titanium dioxide | 2mg |
Preparation technology:
(1) containing the preparation of pill core
The Dexlansoprazole of recipe quantity, magnesium carbonate, sodium sulfite, low-substituted hydroxypropyl cellulose are added in concentration 5% hydroxypropyl cellulose solution, stir, in colloid mill, grind 10min, obtain containing pill core coating solution; Celphere is placed in to fluid bed granulator, coating.Add coating and be placed on drying under reduced pressure 12h in 40 DEG C of vacuum drying ovens.
(2) preparation of isolation coat layer
Take recipe quantity titanium dioxide, Pulvis Talci is scattered in concentration 5% hydroxypropyl methylcellulose solution, after stirring, grinds 10min in colloid mill; Obtain sealing coat coating solution.To be placed in fluid bed granulator containing pill core, coating.Coating is placed on drying under reduced pressure 12h in 40 DEG C of vacuum drying ovens.
(3) preparation of enteric coat layer
Take recipe quantity L30D-55 and add appropriate purified water dilution, obtain solution A; Take recipe quantity PEG6000 and be dissolved in purified water, add recipe quantity Pulvis Talci, titanium dioxide, after stirring, in colloid mill, grind 10min, obtain solution B; Solution B, under stirring condition, is added in solution A, after low rate mixing 30min, cross 80 mesh sieves, obtain enteric coating liquid.To be placed in fluid bed granulator containing pill core, coating.Coating is placed on drying under reduced pressure 12h in 40 DEG C of vacuum drying ovens.
(4) micropill is incapsulated and be get final product.
embodiment 3
Prescription: Dexlansoprazole slow releasing capsule
| Containing pill core | ? |
| Dexlansoprazole | 60mg |
| Magnesium carbonate | 36mg |
| Sodium sulfite | 30mg |
| Low-substituted hydroxypropyl cellulose | 18mg |
| Celphere | 40mg |
| Hydroxypropyl methylcellulose | 15 mg |
| Isolation coat layer (pressing ball core weightening finish 10% ~ 12% calculates): | ? |
| Hydroxypropyl methylcellulose | 7.5 mg |
| Titanium dioxide | 3mg |
| Pulvis Talci | 4.5mg |
| Enteric coat layer 1(is by bag 15% calculating of increasing weight after sealing coat): | ? |
| L30D-55 | 70mg |
| Pulvis Talci | 5mg |
| PEG6000 | 2mg |
| Titanium dioxide | 2mg |
| Enteric coat layer 2(is by bag 70% calculating of increasing weight after sealing coat): | ? |
| S100 | 32mg |
| L100 | 8mg |
| Pulvis Talci | 20mg |
| Triethyl citrate | 4mg |
Preparation technology:
(1) containing the preparation of pill core
The Dexlansoprazole of recipe quantity, magnesium carbonate, sodium sulfite, low-substituted hydroxypropyl cellulose are added in 5% hydroxypropyl methylcellulose solution, stir, in colloid mill, grind 10min, obtain containing pill core coating solution; Celphere is placed in to fluid bed granulator, coating.Add coating and be placed on drying under reduced pressure 12h in 40 DEG C of vacuum drying ovens.
(2) preparation of isolation coat layer
Take recipe quantity titanium dioxide, Pulvis Talci is scattered in 5% hydroxypropyl methylcellulose solution, after stirring, grinds 10min in colloid mill; Obtain sealing coat coating solution.To be placed in fluid bed granulator containing pill core, coating.Coating is placed on drying under reduced pressure 12h in 40 DEG C of vacuum drying ovens.
(3) preparation of enteric coat layer 1
Take recipe quantity L30D-55 and add appropriate purified water dilution, obtain solution A; Take recipe quantity PEG6000 and be dissolved in purified water, add recipe quantity Pulvis Talci, titanium dioxide, after stirring, in colloid mill, grind 10min, obtain solution B; Solution B, under stirring condition, is added in solution A, after low rate mixing 30min, cross 80 mesh sieves; Obtain enteric coating liquid.Micropill is placed in to fluid bed granulator, coating.Coating is placed on drying under reduced pressure 12h in 40 DEG C of vacuum drying ovens.
(4) preparation of enteric coat layer 2
Take recipe quantity L100, S100 and be dissolved in dehydrated alcohol, obtain solution A; Take recipe quantity Pulvis Talci, triethyl citrate is scattered in purified water, grinds 10min in colloid mill, obtains solution B; Under stirring condition, solution B is added in solution A, low rate mixing, obtains enteric coating liquid 2.Isolation micropill is placed in to fluid bed granulator, coating.Coating is placed on drying under reduced pressure 12h in 40 DEG C of vacuum drying ovens.
(5) get after the micropill of 30% enteric layer coating 1 and the micropill mix homogeneously of 70% enteric layer coating 2, incapsulate and get final product.
embodiment 4
Prescription: Dexlansoprazole enteric coated micropill
| Contain pill core: | ? |
| Dexlansoprazole | 24mg |
| Magnesium carbonate | 36mg |
| Sodium sulfite | 30mg |
| Low-substituted hydroxypropyl cellulose | 18mg |
| Celphere | 40mg |
| Hydroxypropyl cellulose | 15 mg |
| Isolation coat layer (pressing ball core weightening finish 10% ~ 12% calculates): | ? |
| Hydroxypropyl methylcellulose | 7.5 mg |
| Magnesium carbonate | 5mg |
| Titanium dioxide | 3mg |
| Pulvis Talci | 4.5mg |
| Enteric coat layer (by 15% calculating of increasing weight after bag sealing coat): | ? |
| L30D-55 | 70mg |
| Pulvis Talci | 5mg |
| Titanium dioxide | 2mg |
Preparation technology:
(1) containing the preparation of pill core
The Dexlansoprazole of recipe quantity, magnesium carbonate, sodium sulfite, low-substituted hydroxypropyl cellulose are added in 5% hydroxypropyl cellulose solution, stir, in colloid mill, grind 10min, obtain containing pill core coating solution; Celphere is placed in to fluid bed granulator, coating.Add coating and be placed on drying under reduced pressure 12h in 40 DEG C of vacuum drying ovens.
(2) preparation of isolation coat layer
Take recipe quantity titanium dioxide, magnesium carbonate, Pulvis Talci and be scattered in 5% hydroxypropyl methylcellulose solution, after stirring, in colloid mill, grind 10min; Obtain sealing coat coating solution.To be placed in fluid bed granulator containing pill core, coating.Coating is placed on drying under reduced pressure 12h in 40 DEG C of vacuum drying ovens.
(3) preparation of enteric coat layer
Take recipe quantity L30D-55 and add appropriate purified water dilution, obtain solution A; Take recipe quantity Pulvis Talci, titanium dioxide in purified water, after stirring, in colloid mill, grind 10min, obtain solution B; Solution B, under stirring condition, is added in solution A, after low rate mixing 30min, cross 80 mesh sieves; Obtain enteric coating liquid.Micropill is placed in to fluid bed granulator, coating.Coating is placed on drying under reduced pressure 12h in 40 DEG C of vacuum drying ovens.
embodiment 5
Prescription: Dexlansoprazole enteric coatel tablets
| Pastille label: | ? |
| Dexlansoprazole | 24mg |
| Magnesium carbonate | 36mg |
| Sodium sulfite | 30mg |
| Low-substituted hydroxypropyl cellulose | 18mg |
| Lactose | 21mg |
| Microcrystalline Cellulose | 20mg |
| Hydroxypropyl methylcellulose | 15 mg |
| Isolation coat layer (pressing label weightening finish 10% ~ 12% calculates): | ? |
| Hydroxypropyl methylcellulose | 7.5 mg |
| Magnesium carbonate | 5mg |
| Titanium dioxide | 3mg |
| Pulvis Talci | 4.5mg |
| Enteric coat layer (by 15% calculating of increasing weight after bag sealing coat): | ? |
| L30D-55 | 70mg |
| Pulvis Talci | 5mg |
| Titanium dioxide | 2mg |
Preparation technology:
(1) preparation of pastille label
Dexlansoprazole is crossed 80 mesh sieves with lactose, microcrystalline Cellulose, magnesium carbonate, sodium sulfite, low-substituted hydroxypropyl cellulose and is mixed homogeneously; in centrifugal granulator; 5% hydroxypropyl methylcellulose solution is as binding agent, adds in the medicated powder of mix homogeneously and mix homogeneously, crosses 18 mesh sieves and granulates.Put into 40 DEG C, baking oven and be dried 12 hours, cross 20 mesh sieve granulate, tabletting, obtains label.
(2) preparation of isolation coat layer
Take recipe quantity titanium dioxide, magnesium carbonate, Pulvis Talci and be scattered in 5% hydroxypropyl methylcellulose solution, after stirring, in colloid mill, grind 10min; Obtain sealing coat coating solution.Pastille label is placed in to coating pan, coating.Coating is placed on drying under reduced pressure 12h in 40 DEG C of vacuum drying ovens.
(3) preparation of enteric coat layer
Take recipe quantity L30D-55 and add appropriate purified water dilution, obtain solution A; Take recipe quantity Pulvis Talci, titanium dioxide in purified water, add, after stirring, in colloid mill, grind 10min, obtain solution B; Solution B, under stirring condition, is added in solution A, after low rate mixing 30min, cross 80 mesh sieves; Obtain enteric coating liquid.Sheet is placed in to coating pan, coating.Coating is placed on drying under reduced pressure 12h in 40 DEG C of vacuum drying ovens.
embodiment 6(control Example)
Prescription: Dexlansoprazole enteric coated capsule
| Containing pill core | ? |
| Dexlansoprazole | 30mg |
| Magnesium carbonate | 18mg |
| Low-substituted hydroxypropyl cellulose | 18mg |
| Celphere | 40mg |
| Hydroxypropyl cellulose | 15 mg |
| Isolation coat layer (pressing ball core weightening finish 10% ~ 12% calculates): | ? |
| Hydroxypropyl methylcellulose | 7.5mg |
| Titanium dioxide | 3mg |
| Pulvis Talci | 4.5mg |
| Enteric coat layer (by 15% calculating of increasing weight after bag sealing coat): | ? |
| L30D-55 | 70mg |
| Pulvis Talci | 5mg |
| PEG6000 | 2mg |
| Titanium dioxide | 2mg |
Preparation technology is with embodiment 2.
embodiment 7, medicine stability research
The embodiment of the present invention 1, embodiment 2, embodiment 3, embodiment 4, embodiment 5, the prepared Dexlansoprazole preparation of embodiment 6 carry out accelerated stability test research.
According to 2010 editions two annex XIX C of Chinese Pharmacopoeia " crude drug and pharmaceutical preparation stability test guideline ", sample is placed in to 30 DEG C ± 2 DEG C of temperature, under the condition of relative humidity 65% ± 5%, place 6 months, sample respectively 1st month, 2 months, 3 months, 6 the end of month in duration of test, measure catabolite 2-3-methyl-4-(2,2,2-trifluoro ethoxy)-1-oxygen-2-picolyl sulfoxide group-1H-benzimidazole, the situation of change that accounts for whole preparation degree of following abbreviation impurity A, the results are shown in Table 1.
Table 1 accelerated stability test is investigated result
As can be seen from Table 1, along with the medicine increase of standing time, the catabolite A causing because medicine is unstable increases gradually, but the catabolite amount that embodiment 1 ~ 5 obviously produces than embodiment 6 is few, embodiment 6 is traditional Dexlansoprazole preparation finished products, and embodiment 1 ~ 5th, according to the present invention fill a prescription preparation Dexlansoprazole preparation finished product, in sum, the Dexlansoprazole preparation finished product stability of filling a prescription prepared according to the present invention is higher than conventional Dexlansoprazole preparation finished product, be conducive to slow down the generation of Dexlansoprazole catabolite in long-term put procedure, be beneficial to storage and the effectiveness of preparation finished product.
Claims (8)
1. a Dexlansoprazole compositions, is characterized in that: described compositions is mixed and formed by the component of following weight portion:
Dexlansoprazole 0.5-2 part;
0.6 part of antacid;
0.5 part of antioxidant;
0.3 part of disintegrating agent.
2. a kind of Dexlansoprazole compositions according to claim 1, is characterized in that: described antacid is magnesium carbonate.
3. a kind of Dexlansoprazole compositions according to claim 1, is characterized in that: described antioxidant is sodium sulfite.
4. a kind of Dexlansoprazole compositions according to claim 1, is characterized in that: described disintegrating agent is low substituted hydroxy-propyl.
5. according to a kind of Dexlansoprazole compositions one of claim 1 ~ 4 Suo Shu, it is characterized in that: the preparation of described compositions is more than one preparations in enteric coatel tablets, enteric coated capsule, slow releasing capsule, enteric coated micropill.
6. Dexlansoprazole compositions according to claim 1, is characterized in that: described Dexlansoprazole is 0.5 part.
7. Dexlansoprazole compositions according to claim 1, is characterized in that: described Dexlansoprazole is 1.0 parts.
8. Dexlansoprazole compositions according to claim 1, is characterized in that: described Dexlansoprazole is 1.5 parts.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410367285.2A CN104173342A (en) | 2014-07-30 | 2014-07-30 | (R)-lansoprazole composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410367285.2A CN104173342A (en) | 2014-07-30 | 2014-07-30 | (R)-lansoprazole composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104173342A true CN104173342A (en) | 2014-12-03 |
Family
ID=51954874
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410367285.2A Pending CN104173342A (en) | 2014-07-30 | 2014-07-30 | (R)-lansoprazole composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104173342A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1571659A (en) * | 2001-10-17 | 2005-01-26 | 武田药品工业株式会社 | Granules containing acid-unstable chemical in large amount |
| CN103381268A (en) * | 2012-05-04 | 2013-11-06 | 江苏豪森药业股份有限公司 | Solid pharmaceutical composition including proton pump inhibitor |
-
2014
- 2014-07-30 CN CN201410367285.2A patent/CN104173342A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1571659A (en) * | 2001-10-17 | 2005-01-26 | 武田药品工业株式会社 | Granules containing acid-unstable chemical in large amount |
| CN103381268A (en) * | 2012-05-04 | 2013-11-06 | 江苏豪森药业股份有限公司 | Solid pharmaceutical composition including proton pump inhibitor |
Non-Patent Citations (1)
| Title |
|---|
| 杨琼瑶等: "兰索拉唑肠溶片处方及工艺探讨", 《淮海工学院学报（自然科学版）》, vol. 20, no. 1, 31 March 2011 (2011-03-31), pages 51 - 54 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102448445B (en) | Orally disintegrating coated tablet | |
| TW550090B (en) | Stable oral pharmaceutical dosage forms for acid-unstable drug | |
| ES2708955T3 (en) | Oral formulations of deferasirox | |
| CN102552159B (en) | Rabeprazole sodium enteric-coated micro-pellet and preparation method thereof | |
| US8753682B2 (en) | Dual release oral tablet compositions of dexlansoprazole | |
| US20060051421A1 (en) | Stable pharmaceutical formulations of benzimidazole compounds | |
| JP2023026623A (en) | Pharmaceutical formulation with excellent dissolution property containing esomeprazole and sodium bicarbonate | |
| CN101816641A (en) | Omeprazole quick-release solid preparation and preparation method thereof | |
| EP3329921B1 (en) | Tablet | |
| CN104523654A (en) | Dexlansoprazole sustained-release capsule and preparation method thereof | |
| CN102225202A (en) | Compound preparation containing aspirin and proton pump inhibitor | |
| US9114085B2 (en) | Modified release pharmaceutical compositions of dexlansoprazole | |
| US8758818B2 (en) | Oral tablet compositions of dexlansoprazole | |
| US20130122090A1 (en) | Multiple Unit Tablet Composition | |
| CN103230593A (en) | Medicine composition used for treating gastrointestinal diseases | |
| CN104173342A (en) | (R)-lansoprazole composition | |
| EP2175855B1 (en) | Stable pharmaceutical composition of a water-soluble vinorelbine salt | |
| CN105769824A (en) | Dexlansoprazole slow-release capsule and preparation method thereof | |
| EP2384747A2 (en) | Oral Tablet Compositions Of Dexlansoprazole | |
| KR102146724B1 (en) | Pharmaceutical formulation comprising benzimidazole and preparation method thereof | |
| CN106924737A (en) | Glycine betaine and proton pump inhibitor compound preparation of a kind of stabilization and preparation method thereof | |
| CN103191136A (en) | Compound preparation containing aspirin and ilaprazole sodium and preparation method thereof | |
| EP3545951A1 (en) | Oral tablet composition comprising dexlansoprazole, oral tablet comprising same and method for manufacturing same | |
| KR20110098562A (en) | Oral pharmaceutical composition for preventing or treating a gastroenteric disease comprising ilaprazole and an anti-inflammatory agent | |
| CN103191137A (en) | Compound preparation containing aspirin and proton pump inhibitor and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20141203 |